The landscape of dementia analysis has advanced substantially with the advent of innovative biomarkers, such as amyloid PET scans, tau imaging, and blood-dependent tests that will detect Alzheimer's pathology yrs before indicators arise. While these technological developments depict extraordinary progress in knowing neurodegenerative disorders, the